Envista Holdings Corp is a medical instruments & supplies business based in the US. Envista shares (NVST) are listed on the NYSE and all prices are listed in US Dollars. Envista employs 11,200 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $38.54 |
|---|---|
| 52-week range | $35.24 - $52.03 |
| 50-day moving average | $41.70 |
| 200-day moving average | $43.16 |
| Wall St. target price | $53.75 |
| PE ratio | 19.4118 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.92 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $38.54 from 2022-06-30
| 1 week (2022-06-24) | 0.39% |
|---|---|
| 1 month (2022-06-01) | -8.26% |
| 3 months (2022-04-01) | -19.88% |
| 6 months (2021-12-31) | -14.47% |
| 1 year (2021-07-01) | -11.95% |
|---|---|
| 2 years (2020-07-01) | 80.68% |
| 3 years (2019-06-27) | N/A |
| 5 years (2017-06-27) | N/A |
Valuing Envista stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Envista's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Envista's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Envista shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Envista's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $499.1 million.
The EBITDA is a measure of a Envista's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.5 billion |
|---|---|
| Operating margin TTM | 14.85% |
| Gross profit TTM | $1.5 billion |
| Return on assets TTM | 3.64% |
| Return on equity TTM | 7% |
| Profit margin | 13.6% |
| Book value | $24.79 |
| Market capitalisation | $6.1 billion |
TTM: trailing 12 months
We're not expecting Envista to pay a dividend over the next 12 months.
Over the last 12 months, Envista's shares have ranged in value from as little as $35.24 up to $52.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Envista's is 1.6331. This would suggest that Envista's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands. This segment also offers software packages, which include DTX Studio Implant for treatment planning of dental implants; TX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic to store and access a various clinical patient images. The company's Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, sensors, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.